Company Filing History:
Years Active: 2013
Title: Frederick Ehrgott: Innovator in Cancer Treatment
Introduction
Frederick Ehrgott is a notable inventor based in Killingworth, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating cancer and other hyperproliferative diseases. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
Ehrgott holds a patent for Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines, which are IGF-1R kinase inhibitors for the treatment of cancer. This invention relates to novel compounds of formula (I), where the variable groups are defined in the specification and claims. The patent also covers pharmaceutical compositions containing these compounds and outlines a method of treatment using them for cancer therapy.
Career Highlights
Throughout his career, Frederick Ehrgott has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Bayer Intellectual Property GmbH and Bayer Pharma Aktiengesellschaft. His experience in these organizations has contributed to his understanding of drug development and patenting processes.
Collaborations
Ehrgott has collaborated with esteemed colleagues in his field, including Stephen J. O'Connor and Jacques P. Dumas. These partnerships have likely enriched his research and innovation efforts, leading to advancements in cancer treatment.
Conclusion
Frederick Ehrgott's contributions to the field of cancer treatment through his innovative patent demonstrate his commitment to improving healthcare. His work continues to inspire future advancements in pharmaceutical research and development.